ISRCTN ISRCTN68742385
DOI https://doi.org/10.1186/ISRCTN68742385
EudraCT/CTIS number 2006-003523-36
Secondary identifying numbers NTR50
Submission date
04/08/2005
Registration date
04/08/2005
Last edited
01/08/2016
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Walter M. van den Bergh
Scientific

PO Box 85500
Utrecht
3508 GA
Netherlands

Phone +31 (0)30 2508350
Email w.m.vandenbergh@neuro.azu.nl

Study information

Study designMulti-centre randomised double-blind placebo-controlled parallel-group trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use contact details to request a participant information sheet
Scientific titleMagnesium in Aneurysmal Subarachnoid Haemorrhage (MASH): a phase III clinical trial
Study acronymMASH
Study objectivesThe MASH study is a prospective randomised, placebo-controlled, international multi-centre trial to determine whether magnesium reduces the frequency of poor outcome (death or dependence) in patients admitted within four days after aneurysmal subarachnoid haemorrhage.
Ethics approval(s)Ethics approval received from local ethics committee
Health condition(s) or problem(s) studiedAneurysmal subarachnoid haemorrhage
InterventionMagnesium sulphate 64 mmol/day (or placebo) is started intravenously as soon as possible after informed consent and continued until 20 days after the haemorrhage.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase III
Drug / device / biological / vaccine name(s)Magnesium sulphate
Primary outcome measurePoor outcome (dependence or death) 3 months after the subarachnoid haemorrhage (Rankin 0 - 3 versus Rankin 4 - 5, or death) as assessed with the modified Rankin scale during a telephone interview. Dependence will be defined as a Rankin score greater than 3.
Secondary outcome measures1. No symptoms 3 months after the subarachnoid haemorrhage (Rankin 0 versus Rankin 1 - 5 or death)
2. Global change in Rankin score
Overall study start date01/01/2006
Completion date01/01/2011

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants1200
Key inclusion criteriaAneurysmal subarachnoid haemorrhage
Key exclusion criteria1. Renal failure (creatinine greater than 150)
2. Age less than 18 years
3. Weight less than 50 kg
4. No informed consent
5. Death is imminent
Date of first enrolment01/01/2006
Date of final enrolment01/01/2011

Locations

Countries of recruitment

  • Netherlands

Study participating centre

University Medical Centre Utrecht
Utrecht
3508 GA
Netherlands

Sponsor information

University Medical Centre Utrecht (UMCU) (The Netherlands)
University/education

PO Box 85500
Utrecht
3508 GA
Netherlands

Website http://www.umcutrecht.nl
ROR logo "ROR" https://ror.org/04pp8hn57

Funders

Funder type

University/education

University Medical Centre Utrecht (UMCU) (The Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Other publications meta-analysis 01/09/2011 Yes No
Results article results 07/07/2012 Yes No
Results article substudy results 01/10/2015 Yes No

Editorial Notes

01/08/2016: Publication reference added.